Compounds > 3,3'-diindolylmethane
Page last updated: 2024-10-26

3,3'-diindolylmethane and Cancer of Endometrium

3,3'-diindolylmethane has been researched along with Cancer of Endometrium in 2 studies

3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leong, H2
Riby, JE1
Firestone, GL2
Bjeldanes, LF2

Other Studies

2 other studies available for 3,3'-diindolylmethane and Cancer of Endometrium

ArticleYear
Potent ligand-independent estrogen receptor activation by 3,3'-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways.
    Molecular endocrinology (Baltimore, Md.), 2004, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Anticarcinogenic Agents; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dep

2004
Cytostatic effects of 3,3'-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression.
    Carcinogenesis, 2001, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Alkaline Phosphatase; Anticarcinogenic Agents; Blotting, Northern; Blotting, Western

2001